{"slideshow_credits": null, "snippet": "Valeant, which failed in its attempt to acquire the Botox maker Allergan last year, is now in talks with Salix, according to a person briefed on the matter. The British drug maker Shire, too, is interested.", "abstract": "Valeant, which failed in its attempt to acquire the Botox maker Allergan last year, is now in talks with Salix, according to a person briefed on the matter. The British drug maker Shire, too, is interested.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "David", "role": "reported", "lastname": "GELLES", "rank": 1, "organization": ""}], "original": "By DAVID GELLES"}, "web_url": "http://dealbook.nytimes.com/2015/02/13/drug-maker-salix-is-once-again-a-potential-takeover-target/", "lead_paragraph": null, "headline": {"main": "Drug Maker Salix Is Once Again a Potential Takeover Target", "kicker": "DealBook"}, "_id": "54de366238f0d841787c9638", "word_count": "381", "multimedia": [], "pub_date": "2015-02-13T12:35:47Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Salix Pharmaceuticals Ltd", "rank": "1"}, {"name": "organizations", "value": "Shire PLC", "rank": "2"}, {"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "rank": "3"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "1"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}